plcγ

CCT129957 is a novel and potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of about 3 μM and a GC50 of 15 μM.CCT129957 exhibits anticancer activity and inhibits Ca2+ release in squamous cells.

RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.

3,4'-Dihydroxy-3,5',7-trimethoxyflavan is a flavonoid compound extracted from the stem of Machilus japonica. It is a phospholipase C71 (PLCγ1) inhibitor with anticancer antioxidant activity and can be used to study cancer.

5α-Hydroxycostic acid, a naturally occurring sesquiterpene, inhibits choroidal neovascularization in rats through dual signaling pathways mediated by VEGF/VEGFR and Ang2/Tie2 (angiopoietin 2), and exhibits anti-inflammatory and anti-angiogenic effects on human breast cancer cells

Linocinnamarin (3-[4-(beta-D-Glucopyranosyloxy)phenyl]acrylic acid methyl ester) is isolated from Fragaria ananassa Duch. (strawberry). The inhibition of antigen-stimulated degranulation by LN is mainly due to inactivation of Syk/phospholipase Cgamma (PLCgamma) pathways.

PLC-β-IN-1 (Compound 8a) is an inhibitor of PLCβ that exhibits anti-airway constriction activity by suppressing PLCβ and its downstream signaling pathways. It also enhances the bronchorelaxant effects of β-agonists. This compound can be utilized in asthma research.

PLC thio-PIP2 trisodium is a natural analog of PIP2. In vitro experiments use PLC thio-PIP2 trisodium to simulate the hydrolysis of PIP2 by PLC. This process allows for the quantitative analysis of PLC activity by detecting the free thiol released during hydrolysis.

Vinaxanthone (SM-345431) is a small molecule compound derived from Penicillium chrysogenum that acts as a selective and potent inhibitor of semaphorin3A, phospholipase C (PLC), and FabI, exhibiting antimicrobial activity by blocking intracellular fatty acid synthesis and inhibiting the growth of Staphylococcus aureus.

U-73122 (U73122) , an effective PLC inhibitor, reduces agonist-induced Ca2+ increases in platelets and PMN.

m-3M3FBS is a phospholipase C (PLC) activator.

D609 (Tricyclodecan-9-yl-Xanthogenate) has a wide range of biological activities including antioxidant, antiapoptotic, anticholinergic, antitumor, anti-inflammatory, antiviral, antiproliferative, and neuroprotective activities.D609 acts by inducing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS). D609 acts by causing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS).

Tirbanibulin is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines).

SPK-601 is an inhibitor of phosphatidylcholine-specific phospholipase C.

Tirbanibulin (KX2-391) is a highly selective Src kinase inhibitor that has demonstrated efficacy in pre-Clinicalal animal models of colon, pancreatic, prostate and breast cancer. It is a substrate-targeted kinase inhibitor. KX2-391, belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.

QL-X-138 HCl is a novel selective and highly potent BTK/MNK dual-kinase inhibitor with anticancer activity that binds covalently to BTK and noncovalently to MNK. QL-X-138 HCl inhibited BTK, MNK1, and MNK2 kinases. QL-X-138 HCl has anti-dengue virus 2 activity and shows anti-proliferative activity in acute myeloid leukemia cells. QL-X-138 HCl can be used to study lymphoma and leukemia.

NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).

Quinacrine dihydrochloride (Mepacrine dihydrochloride) is the dihydrochloride salt of the 9-aminoacridine derivative quinacrine with potential antineoplastic and antiparasitic activities.

Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

Tirbanibulin Mesylate (KX01 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines).

QL47 is a host-targeted small molecule antiviral agent with antiviral activity against dengue and other RNA viruses.QL47 acts as an inhibitor of viral translation and a covalent inhibitor of BTK, and can be used in the study of lymphomas.

CP-LC-0867 lipid, an ionizable cationic amino lipid derived from the natural amino acid homocysteine, has demonstrated effective in vivo delivery and highly efficient protein expression for various types of RNA (mRNA, cRNA, and saRNA) without showing signs of toxicity.

Lipid CP-LC-1254, an ionizable cationic amino lipid derived from the natural amino acid homocysteine, has demonstrated efficacious RNA (mRNA, cRNA, and saRNA) delivery in vivo, achieving high levels of protein expression without observed signs of toxicity.

Lipid CP-LC-0729, a cationic amino lipid derived from the natural amino acid homocysteine, has demonstrated efficient in vivo delivery and high-level expression of various types of RNA (mRNA, cRNA, and saRNA) without any observed signs of toxicity.

Lipid CP-LC-1074 is an ionizable cationic amino lipid derived from the natural amino acid homocysteine.